Moreover, the combination regimen showedappreciable tolerability, causing no significant adverse effects during treatment.Collectively, these findings imply that the inhibition of XPO1 activity could be a plausibletherapeutic strategy for overcoming resistance to KRASi as combining Eltanexor with aKRASG12Di can have a durable and synergistic antitumor activity in cancer patients that havedeveloped resistance to therapy with KRASG12Di. Here, XPO1 is linked to cancer.